Novotech Receives CRO Leadership Award for Exceeding Customer Expectations ACN Newswire

Novotech Receives CRO Leadership Award for Exceeding Customer Expectations

CHICAGO, IL, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was awarded a prestigious Clinical Leader and Life Science Leader CRO Leadership Award for exceeding customer expectations, at Drug Information Association 2022 (DIA 2022).Novotech CEO Dr. John Moller said the company was extremely pleased to receive this award for the second consecutive year. "Receiving this recognition from our clients is incredibly important to us and is an endorsement of our service delivery model that is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem solving, ownership and flexibility, and our investments in data and technology ensure clients have real time access to trial performance."Book a meeting with one of the Novotech experts at DIA here. https://novotech-cro.com/contactClinical Leader and Life Science Leader working with Industry Standard Research (ISR), selected Novotech for the CRO Leadership Award.According to the CRO Leadership Award research team: "The awards are based on customer feedback. Winning CROs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. Primary market research by ISR Reports is the basis of the awards. Sponsors provide ratings of CROs based on recent outsourced projects. This experiential feedback is analyzed by sponsor company size to reveal leading CROs in different performance categories."Ed Miseta, Chief Editor for Clinical Leader said: "Selecting the right CRO can make or break your project. It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. Regardless of whether you are concerned about compatibility, capabilities, expertise, quality, or reliability. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. We are grateful to our colleagues at ISR Reports for conducting the research necessary to produce these awards. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for the work ethic they exhibit in consistently meeting the needs of their drug development clients."Kevin Olson, CEO of Industry Standard Research said: "Industry Standard Research (IRS) continues to consider it an honor to provide the primary market research data for Life Science Leader and Clinical Leader's CRO Leadership Awards. ISR's stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research. This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enable users of ISR's market research to make confident business decisions based on the experiences of their industry peers."Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said Novotech's Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions. "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."About Novotech Health Holdings Pte Ltd ("Novotech")Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Toyota Announces July Production Plan JCN Newswire

Toyota Announces July Production Plan

Toyota City, Japan, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - We at Toyota would like to again apologize for the repeated adjustments to our production plans due to the parts shortage resulting from the spread of COVID-19, and for causing considerable inconvenience to our customers who have been waiting for the delivery of vehicles, suppliers, and other parties concerned.The global production volume for July is expected to be approximately 800,000 units (approx. 250,000 units in Japan and 550,000 units overseas). We have revised the global production plan by about 50,000 units from the number provided to our suppliers at the beginning of the year.As for July, we previously announced that some plants in Japan will suspend operations ("Adjustments to domestic production in June and July"). However, due to the continued impact of a COVID-19 outbreak at one of our suppliers, we have decided to extend the period of operations suspension at some of our plants and production lines.The global production volume for July through September is estimated to average about 850,000 units per month. The production forecast for the fiscal year remains unchanged (approx. 9.7 million).As it remains difficult to look ahead due to the shortage of semiconductors and the spread of COVID-19, there is a possibility that the production plan may be lower. However, we will examine the parts supply closely to minimize sudden decreases in production, and continue to make every effort possible to deliver as many vehicles to our customers at the earliest date.For the revised domestic operations suspension schedule for July, visit https://global.toyota/en/newsroom/corporate/37487297.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal JCN Newswire

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

TOKYO, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model, AD Archimedes Condition Event (AD ACE) model1,2,3 from the healthcare payer and societal perspectives in the United States, in the peer-reviewed journal Neurology and Therapy. This is the second publication of lecanemab's potential value. It follows the evaluation of the long-term health outcomes using simulation modeling of lecanemab published in Neurology and Therapy in April 2022.4 While the healthcare payer perspective focuses on direct care costs (e.g., outpatient and inpatient services, medications, intervention costs, nursing home and home healthcare services), the societal perspective further considers societal costs (e.g., productivity loss and informal care costs). As reported in the previous publication, it was suggested that compared to standard of care* (SoC), individuals treated with lecanemab in addition to SoC (lecanemab+SoC) may potentially experience slower disease progression to mild, moderate and severe AD from baseline by 2.51, 3.13 and 2.34 years on average, respectively. The preliminary results of this model-based simulation could possibly translate into additional quality-adjusted life years (QALY**) and reduction in the formal and informal care costs***. Additionally, the AD ACE model framework used in this study allowed assessment of the potential value of lecanemab in different scenarios and sensitivity analyses, including the impact of patient subsets, alternative treatment stopping rules**** and potential dosing regimens as well as major sources of uncertainty. Eisai is committed to conducting and sharing these types of clinical and socioeconomic analyses to establish trust as we work to potentially bring lecanemab to people living with early AD who have confirmed presence of amyloid pathology in the brain. To that end, Eisai would like to provide a common foundation for stakeholders' discourse regarding the potential clinical and socioeconomic value of lecanemab from the societal perspective, not to assign a price for lecanemab at this time. This model-based simulation was conducted using the results of a Phase 2b clinical trial (Study 201) evaluating the efficacy and safety of lecanemab for early AD with confirmed amyloid pathology as well as published literature. It also estimated the potential economic value of lecanemab+SoC over a broad range of willingness-to-pay thresholds from $50,000 to $200,000 per QALY gained as recommended by the Institute for Clinical and Economic Review (ICER)*****. Lecanemab+SoC was predicted to result in a gain of 0.61 QALYs and a decrease in total non-treatment costs of $8,707 per person from the healthcare payer perspective (Societal perspective: 0.64 QALYs gain and $11,214 decrease) compared to the SoC for patients with early AD who have confirmed presence of amyloid pathology. The potential annual value-based price (VBP) of lecanemab was estimated at $9,249 to $35,605 (Societal perspective: $10,400 to $38,053) based on this early economic assessment. ICER's value framework5 indicates that value cannot be wholly derived from measures of clinical and cost-effectiveness, so contextual considerations and an examination of other benefits and disadvantages are also added into the framework when assessing long-term value. This may lead to using the societal perspective and higher end of the broad range of willingness-to-pay threshold in estimating the justifiable price of lecanemab, given the large societal burden of AD relative to direct healthcare costs. Many people living with AD received informal care from their family and friends totaling more than 16 billion hours of unpaid care valued at $271.6 billion in the U.S. in 2021.6 These predicted and simulated findings suggest that early treatment with lecanemab may reduce these costs and economic burdens, and provide insights for healthcare decision-makers regarding the potential clinical and socioeconomic value of lecanemab. The Phase 3 lecanemab Clarity AD data will soon be available to inform the model inputs and refine the findings. In the event that lecanemab receives the U.S. Food and Drug Administration's (FDA) approval, Eisai may determine a VBP using this framework along with other considerations, such as affordability, health system sustainability, etc. "Eisai's goal is to create therapies, such as our investigational anti-amyloid beta protofibril antibody lecanemab, that may help impact the anxieties of people living with Alzheimer's disease and their families. For Alzheimer's disease, it is important to evaluate the holistic value of therapies taking into account not only medical costs but also the immense societal costs," said Ivan Cheung, Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd., Chairman and CEO, Eisai Inc. "As part of Eisai's commitment to our human health care mission, trust and transparency, we will continue to publish data and information about lecanemab and look forward to sharing the results of the lecanemab confirmatory Phase 3 Clarity AD clinical trial this fall." Eisai completed lecanemab's rolling submission of a Biologics License Application (BLA) for the treatment of early AD to the FDA under the accelerated approval pathway in May 2022. The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the fall of 2022. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA during Eisai's fiscal year 2022, which ends in March2023. In Japan, in March 2022, Eisai initiated submission of application data to the Pharmaceuticals and Medical Devices Agency (PMDA) under the prior assessment consultation system with the goal of obtaining early approval for lecanemab, and aims to file for the manufacturing and marketing approval based on the results of Clarity AD during Eisai's fiscal year 2022. Also, in Europe, based on the results of the Clarity AD study, Eisai plans to submit a new drug application in fiscal year 2022. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval. * Standard of Care (SoC) for AD currently consists of lifestyle modifications and pharmacologic treatment of symptoms.** The quality-adjusted life year (QALY) is a measure of the value of health outcomes. Since health is a function of length of life (i.e., quantity) and quality of life (QOL), the QALY was developed as an attempt to combine the value of these attributes into a single index number. One QALY equates to one year in perfect health. QALY scores range from 1 (full health) to 0 (dead). For example, a new intervention may increase length of life by 3 years and improve quality of life by 70% (QALY score of 2.1) compared to an existing intervention that may increase length of life by 3 years and only improve QOL by 50% (QALY score of 1.5), the incremental QALY for this new intervention will be 0.6 QALYs.*** Formal and informal care costs do not include lecanemab drug cost.**** Alternative treatment stopping rules were explored in scenario analyses where treatment with lecanemab was stopped after a fixed duration of 1.5, 3 and 5 years.***** ICER is a non-profit research organization in the U.S. that evaluates the evidence on the clinical and economic value of prescription drugs, medical tests, devices and health system delivery innovations. 1 Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer's disease Archimedes condition-event simulator: Development and validation. Alzheimers Dement (NY). 2018;4:76-88. Published 2018 Feb 16. doi:10.1016/j.trci.2018.01.001.2) Tafazzoli and Kansal. Disease simulation in drug development, External validation confirms benefit in decision making. The Evidence Forum. 2018. bit.ly/3NgEeDD(3) Tafazzoli A, Weng J, Sutton K, et al. Validating simulated cognition trajectories based on ADNI against 436 trajectories from the National Alzheimer's Coordinating Center (NACC) dataset. 11th edition of Clinical Trials on 437 Alzheimer's Disease (CTAD); Barcelona, Spain: 2018.(4) Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. Neurol Ther 11, 863-880 (2022). https://link.springer.com/article/10.1007/s40120-022-00350-y.(5) ICER Value Framework 2020-2023. 2022. bit.ly/39HjYO3(6) Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures 2022 Available from: bit.ly/3bkCR9VMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Eisai Inc. USLibby HolmanLibby_Holman@Eisai.com201-753-1945 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
CIMB Niaga and JCB launch JCB Digital Credit Card in Indonesia ACN Newswire

CIMB Niaga and JCB launch JCB Digital Credit Card in Indonesia

TOKYO & JAKARTA, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - PT Bank CIMB Niaga Tbk (CIMB Niaga) and PT JCB International Indonesia (JCB), as a subsidiary of JCB International Co. Ltd., launched the CIMB Niaga JCB OCTO Card Digital Credit Card in Jakarta, on 22nd June 2022. This credit card with digital or virtual technology was developed in line with the rapid growth of demand for online transactions and credit card technology. The Digital Credit Card provides a number of improvements. It enables the user to apply for CIMB Niaga JCB OCTO Card Digital Credit Card anytime and anywhere, and it also provides a safer and easier payment method for online transactions by using a one-time password (OTP).Director of Consumer Banking CIMB Niaga Noviady Wahyudi said, "CIMB Niaga continues to innovate to develop digital customer experience by integrating various products and services into the OCTO Mobile Super App, making it easier for people to meet their financial needs. Recently, we innovated to present the CIMB Niaga JCB OCTO Card Digital Credit Card, which provides a comprehensive digital transaction experience for users," said Noviady.Meanwhile, President Director of PT JCB International Indonesia, Takumi Takahashi, said, "The launching of this new Digital Credit Card shows our successful collaboration with CIMB Niaga and our commitment to cater to the demand for digital transactions in Indonesia. We believe with this new Digital Credit Card, customers can experience the uniqueness of JCB."The issuance of the CIMB Niaga JCB OCTO Card Digital Credit Card is an initiative of CIMB Niaga and JCB to provide an easier, faster and safer online transaction experience. All transactions will be verified by entering a random two (2) digit OCTO Mobile PIN, and online transactions at most online merchants that have implemented 3D secure security are protected by a one time password (OTP) sent to a mobile phone number registered with the Bank. These features minimize the risk of online fraud and losses due to card theft. Customers also have the option to immediately block their CIMB Niaga JCB OCTO Card Digital Credit Card via the CIMB Niaga OCTO Mobile.With the fast online application process for the Digital Credit Card, customers will have easier and instant access to their credit cards at the time of payment, without the hassle of carrying a physical credit card. Overall, this new Digital Credit Card is a convenient and hassle-free way to do transactions instantly.The main features and benefits of this Digital Credit Card include 10% cash back for online transactions through the CIMB Niaga OCTO Mobile, a free installment fee with a 3 month tenor for minimum retail transactions of Rp 500,000, and a free annual fee. For detailed information, please visit: https://www.cimbniaga.co.id/id/personal/kartu-kredit/octo-card.CIMB Niaga JCB OCTO Card Digital Credit Card customers can use the Card with the above features and benefits at more than 100 thousand offline and online merchants in Indonesia.About CIMB Niaga CIMB Niaga was established under the name of Bank Niaga in 1955. Approximately 92.5% of CIMB Niaga's shares (including those owned by PT Commerce Kapital of 1.02%) are owned by the CIMB Group. CIMB Niaga offers complete banking products and services, both conventional and Sharia, through a 428 office network as of 30 June 2021, consisting of 358 branch offices, 37 Digital Lounges and 33 Mobile Branches. CIMB Niaga has 12,389 employees (consolidated) as of June 30, 2021.CIMB Group is the second largest financial services provider in Malaysia and one of the leading universal banking groups in ASEAN. The products and services it offers include consumer banking products and services, investment banking, Islamic banking, asset management and insurance. CIMB Group is headquartered in Kuala Lumpur, and operates in all ASEAN member countries (Malaysia, Indonesia, Thailand, Singapore, Cambodia, Brunei, Vietnam, Myanmar, Laos, and the Philippines). In addition to the ASEAN region, CIMB Group has also established offices in China, Hong Kong, India, Sri Lanka, the United States, the United Kingdom, and Korea. CIMB Group's shares are listed on Bursa Malaysia through CIMB Group Holdings Berhad. As of 30 June 2021, the group has a market capitalization value of USD 11.1 billion.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 39 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 140 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAyaka NakajimaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@jcb.co.jp Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SMEStreet GameChangers Forum 2022 to be Inaugurated on World MSME Day ACN Newswire

SMEStreet GameChangers Forum 2022 to be Inaugurated on World MSME Day

SMEStreet Foundation with the support from MSME Ministry, Govt of India, EDII- Ahmedabad, NSIC is excited to introduce SMEStreet GameChangers Forum 2022 is set to start on Theme of Acknowledging Role of Indian MSMEs in 5 Trillion Dollar Economy ChaseNEW DELHI, June 22, 2022 - (ACN Newswire via SEAPRWire.com) - While the nation is celebrating Azadi ka Amrit Mahotsav this year, this World MSME Day, We are excited to bring this year’s season of SMEStreet Game Changers Forum. As you know, we, at SMEStreet is working in the area of MSMEs’ upliftment and development since 2014. Our aim is to ensure an optimised contribution of MSMEs in developing the Economy. This year, the core theme of SMEStreet Game Changers Forum 2022 is acknowledging the Role of MSMEs in chasing the Target of 5 Trillion Dollar Economy.In this bid, we are conducting the inaugural webinar of the SMEStreet GameChnagers Forum 2022 on June 27th 2022 at 4:30 PM. These webinars will focus on highlighting opportunities for MSMEs which can help MSMEs maximise their Contribution to the Chase of 5 Trillion Dollar Economy Target.Chief Guest of the Inaugural Session of SMEStreet GameChangers Forum 2022 will be Shri BB Swain, Secretary, MSME Ministry, Government of India. He will speak on his ministry’s vision and plan for Indian MSMEs in achieving next-level economic growth and build a strong momentum towards PM Shri Narendra Modi’s Vision of India, which is an economic leader for the world and becoming a 5 Trillion Dollar Economy.And we at SMEStreet are committed to making the best out of every single opportunity to recognise the MSMEs’ Potential and contribute in making the MSME ecosystem proactively for MSME Development through knowledge sharing."MSMEs in India are at a very critical period. We have witnessed which we never wanted to see in our lives in the COVID era. But, now, the demand of the time is to look beyond the challenges and move ahead. Explore opportunities and evaluate every single possibility which can make your business a better one. With this initiative we aim to highlight and acknowledge contemporary trends and opportunities that are existing for the MSME sector. The entire activity of SMEStreet Game Changers 2022 will add to the previous two-years of game changing activity for bringing a positive curve into MSMEs' growth story," says Faiz Askari, Founder and Editor of SMEStreet.SMEStreet GameChangers Forum 2022The Forum is aimed to highlight, showcase and recognize the potential of the Indian MSMEs and for the Indian MSMEs. An interactive showcase of knowledge and networking for MSMEs will emphasize opportunities and explain the roadmap to achieve those opportunities.In this initiative, we will highlight and showcase opportunities for MSMEs to explore growth which will not just transform their respective businesses but also make their contribution in making India- A Truly a World Leading Nation from the perspective of MSMEs Landscape.Key Supporting Agencies and OrganizationsMinistry of MSME, Govt of IndiaNSICEntrepreneurship Development Institute of India, AhmedabadLexcomplySMEStreet FoundationAlmond-VirtexGlobal Organizations Supporting SMEStreet GameChangers 2022UNISMO, BahrainAASGON, Africa- EuropeUnited Nations Global CompactGGIS, United KingdomKey Activities at SMEStreet GameChangers Forum 2022Series of WebinarsSMEStreet Report: Industry 4.0 Among Indian MSMEsPodcastsThought-Provoking ArticlesMSME Success StoriesOpportunity Showcase for StartupsThe ImpactOver 3.5 Million CXOs from MSMEs are expected to witness this event series through various digital media platforms including SMEStreet.inLive Streaming on SMEStreet.inFacebook – facebook.com/smestreet.inYoutube – SMEStreet ViewPointSocial Media Broadcast at 1600 Hrs (4:30 PM IST) onMonday, June 27th 2022About SMEStreet GameChangers Forum 2021Started in 2020 after the COVID outbreak, SMEStreet GameChangers Forum is a campaign to recognise the influencers who contributed a strong, proactive and smart strategy in pursuit of growth. SMEStreet featured SMEStreet GameChangers 2020 List naming Union Minister MSME, Shri Nitin J Gadkari And UP’s MSME Minister Shri Siddharth Nath Singh among India’s key influencers (GameChangers) who contributed significantly in transforming the pandemic crisis into an opportunity for MSMEs to fightback from COVID.The SMEStreet GameChangers Forum 2021 witnessed Union Minister, Hon’ble Shri Nitin J Gadkari as the Chief Guest and Governor of Kerala, Hon’ble Shri Arif Mohammad Khan as the Guest of Honour of the SMEStreet GameChangers Forum 2021 on June 19th 2021.The list of personalities includes Shri Nitin Gadkari, MSME Minister, Govt. of India, Shri Siddharth Nath Singh, MSME Minister for Uttar Pradesh Govt., Mr. Vinai K Saxena Chairman of KVIC/ (Now Lt. Governor of Delhi), Shri Abhishek Singh, CEO MyGov, Mr. Nikhil Arora Managing Director of GoDaddy, Shri Arun Kumar Jha, DG NPC and Mr. Tejas Goenka of Tally Solutions are among top listed Game Changers of SMEStreet GameChanger 2020 List.About the Inaugural of SMEStreet GameChangers Forum 2021SMEStreet GameChangers Forum Inaugural Session on June 15 2021Key Highlights of the Inaugural Session of SMEStreet GameChangers ForumUnion MSME Minister, Hon’ble Shri Nitin Gadkari delivered Special Keynote SessionGovernor of Kerala, Hon’ble Shri Arif Mohammad Khan delivered a Special Inaugural Address on MSME Entrepreneur Motivation. Shri BB Swain, Secretary MSME participated and delivered his vision & Plan for MSME development. Union Minister Shri Nitin Gadkari made a remarkable Announcement of Easing out the MSME Registration Process at the SMEStreet GameChangers Forum.Distinguished Industry Leaders Participated in the Event. Youtube Link: youtu.be/2t99VxqGgyEAbout SMEStreetStarted in 2014, SMEStreet is an ecosystem for MSMEs and Startups which are aiming to grow to the next level. This knowledge driven platform is beyond just a media, it aims to highlight opportunities that are existing for small businesses and it also provides a guided approach for MSMEs to chase and capitalize those opportunities. For more information, contact:Faiz@smestreet.in+91-9871762630 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Tracing Pertamina’s cost efficiency amid high global oil prices ACN Newswire

Tracing Pertamina’s cost efficiency amid high global oil prices

JAKARTA, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - State-owned oil and gas firm PT Pertamina (Persero) succeeded in achieving cost optimization of US$2.21 billion in 2021 amid high global crude oil prices.Pertamina. gas station ANTARA/HO - PT. Pertamina Patra Niaga Regional Kalimantan."Through this business strategy, in 2021, Pertamina succeeded in cost optimization of US$2.21 billion, obtained from the cost savings program (cost-saving) of US$1.36 billion, cost avoidance of US$356 million, and additional revenue (revenue growth) of around US$495 million," director of finance of Pertamina, Emma Sri Martini, said in Jakarta on Tuesday.Martini explained that Pertamina has developed several policies and business strategies from the financial and operational perspective to face the increasing global oil price challenges.Pertamina is strengthening its financial strategy and operational efforts to improve efficiency across business lines, both holdings and sub-holdings and from upstream processing to downstream, amid increasing crude oil prices.From a financial perspective, Pertamina has implemented a cost optimization program across the Pertamina Group, including cost savings, cost avoidance, and increased revenue.Under the savings efforts, Pertamina is also running a hedging program for market risk management. In addition, the company has centralized procurement, prioritized capital expenditures, and is managing assets and liabilities to reduce costs or interest expenses (cost of funds)."We are trying to optimize all costs and manage the company's financial aspects, to reduce costs, including prioritizing projects that have fast results," she said.Besides financial tightening, Pertamina is also implementing an operational strategy to increase revenue for its six sub-holdings.In the upstream business, Pertamina has continued to increase oil and gas production and lifting to take advantage of the increasing oil prices. As a result, production has increased by 4 percent and lifting by 3 percent.The positive performance from upstream operations has been contributed by Rokan Block and foreign assets and consistent efforts to maintain production levels through well-drilling and resource discovery. In 2021, Pertamina drilled 12 exploration wells and 350 exploitation wells. In the same year, its discovered reserves (2C) reached 486.70 MMBOE (million barrels of oil equivalent) and additional proven reserves (P1) reached 623.47 MMBOE.In processing and petrochemicals, in 2021, Pertamina implemented a crude and product optimization strategy. This contributed to an increase in product yield value by around 3 percent. The strategy is related to the selection and economic substitution of crude oil and maximizing high valuable products with high spreads. In 2021, refinery production also increased in response to higher energy demand due to national economic recovery.Then, in the transportation and logistics sectors, Pertamina optimized the load factor to achieve revenue and cost-efficiency. In the gas business, Pertamina also increased the gas trade volume and transportation, as well as oil transportation volume."And after the legal end state, we will also intensify resource sharing, such as sharing facilities and development agreements, especially in upstream sub-holding," Martini said.She added that the positive performance downstream was also supported by the government through the recognition of the difference in compensation for HJE JBT Solar and JBKP Pertalite in 2021, which reached around US$4 billion or equivalent to Rp58.6 trillion (excluding tax) and around US$1.7 billion or equivalent to Rp24.1 trillion (excluding tax) in 2018 and 2019. According to Martini, the government's support will continue in 2022 through a policy revision that will stipulate Pertalite (RON90) as a Special Assignment Fuel in place of Premium (RON88) and an adjustment to the price of Pertamax.As Pertamina's appreciation for this support, several initiatives in the downstream sector have been implemented that simultaneously respond to market changes, such as an expansion of digital transactions, acceleration of Pertashop outlets to capture larger market opportunities in rural areas, and diversion of gas station energy sources to solar panels.We appreciate the government and the DPR's decision, which has increased the budget ceiling for subsidies and compensation for 2022 to maintain and protect people's purchasing power and contain potential inflation. This is a support for Pertamina in providing energy amidst the challenges of high crude oil prices," Martini said.With this support, in 2022, Pertamina will make efforts to increase oil and gas production by 17 percent, targeting 79.9 percent Valuable Product Yield, adding around 3 thousand Pertashop fuel outlets, developing digital markets for up to 25 million MyPertamina users, and increasing revenue from non-captive markets in the shipping business to 7.5 percent.To strengthen its commitment to low-carbon energy, it will produce 7,138 GWh of electricity, which will be supported by a targeted increase in the installed capacity of up to 2.9 GW. Another important strategy will be unlocking the value developed by subsidiaries."In the financial sector, we will focus on optimizing costs targeted to reach up to US$600 million. We will continue to communicate with the government to ensure a good decision for the company," Martini said.Jakarta (ANTARA) - State-owned oil and gas firm PT Pertamina (Persero) succeeded in achieving cost optimization of US$2.21 billion in 2021 amid high global crude oil prices."Through this business strategy, in 2021, Pertamina succeeded in cost optimization of US$2.21 billion, obtained from the cost savings program (cost-saving) of US$1.36 billion, cost avoidance of US$356 million, and additional revenue (revenue growth) of around US$495 million," director of finance of Pertamina, Emma Sri Martini, said in Jakarta on Tuesday.Martini explained that Pertamina has developed several policies and business strategies from the financial and operational perspective to face the increasing global oil price challenges.Pertamina is strengthening its financial strategy and operational efforts to improve efficiency across business lines, both holdings and sub-holdings and from upstream processing to downstream, amid increasing crude oil prices.From a financial perspective, Pertamina has implemented a cost optimization program across the Pertamina Group, including cost savings, cost avoidance, and increased revenue.Under the savings efforts, Pertamina is also running a hedging program for market risk management. In addition, the company has centralized procurement, prioritized capital expenditures, and is managing assets and liabilities to reduce costs or interest expenses (cost of funds)."We are trying to optimize all costs and manage the company's financial aspects, to reduce costs, including prioritizing projects that have fast results," she said.Besides financial tightening, Pertamina is also implementing an operational strategy to increase revenue for its six sub-holdings.In the upstream business, Pertamina has continued to increase oil and gas production and lifting to take advantage of the increasing oil prices. As a result, production has increased by 4 percent and lifting by 3 percent.The positive performance from upstream operations has been contributed by Rokan Block and foreign assets and consistent efforts to maintain production levels through well-drilling and resource discovery. In 2021, Pertamina drilled 12 exploration wells and 350 exploitation wells. In the same year, its discovered reserves (2C) reached 486.70 MMBOE (million barrels of oil equivalent) and additional proven reserves (P1) reached 623.47 MMBOE.In processing and petrochemicals, in 2021, Pertamina implemented a crude and product optimization strategy. This contributed to an increase in product yield value by around 3 percent. The strategy is related to the selection and economic substitution of crude oil and maximizing high valuable products with high spreads. In 2021, refinery production also increased in response to higher energy demand due to national economic recovery.Then, in the transportation and logistics sectors, Pertamina optimized the load factor to achieve revenue and cost-efficiency. In the gas business, Pertamina also increased the gas trade volume and transportation, as well as oil transportation volume."And after the legal end state, we will also intensify resource sharing, such as sharing facilities and development agreements, especially in upstream sub-holding," Martini said.She added that the positive performance downstream was also supported by the government through the recognition of the difference in compensation for HJE JBT Solar and JBKP Pertalite in 2021, which reached around US$4 billion or equivalent to Rp58.6 trillion (excluding tax) and around US$1.7 billion or equivalent to Rp24.1 trillion (excluding tax) in 2018 and 2019. According to Martini, the government's support will continue in 2022 through a policy revision that will stipulate Pertalite (RON90) as a Special Assignment Fuel in place of Premium (RON88) and an adjustment to the price of Pertamax.As Pertamina's appreciation for this support, several initiatives in the downstream sector have been implemented that simultaneously respond to market changes, such as an expansion of digital transactions, acceleration of Pertashop outlets to capture larger market opportunities in rural areas, and diversion of gas station energy sources to solar panels.We appreciate the government and the DPR's decision, which has increased the budget ceiling for subsidies and compensation for 2022 to maintain and protect people's purchasing power and contain potential inflation. This is a support for Pertamina in providing energy amidst the challenges of high crude oil prices," Martini said.With this support, in 2022, Pertamina will make efforts to increase oil and gas production by 17 percent, targeting 79.9 percent Valuable Product Yield, adding around 3 thousand Pertashop fuel outlets, developing digital markets for up to 25 million MyPertamina users, and increasing revenue from non-captive markets in the shipping business to 7.5 percent.To strengthen its commitment to low-carbon energy, it will produce 7,138 GWh of electricity, which will be supported by a targeted increase in the installed capacity of up to 2.9 GW. Another important strategy will be unlocking the value developed by subsidiaries."In the financial sector, we will focus on optimizing costs targeted to reach up to US$600 million. We will continue to communicate with the government to ensure a good decision for the company," Martini said.Contact: Fajriyah Usman, VP Corporate Communications, PT Pertamina (Persero)M: +62 858 8330 8686, Email: fajriyah.usman@pertamina.com, URL: https://www.pertamina.comWritten by: Azis Kurmala, Editor: Suharto (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Pertamina posts record net profit of Rp29.3 trillion ACN Newswire

Pertamina posts record net profit of Rp29.3 trillion

JAKARTA, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - State-owned oil and gas firm PT Pertamina (Persero) posted a record net profit of Rp29.3 trillion in 2021 following a successful business transformation.President director of Pertamina, Nicke Widyawati, addressing an online press conference on Pertamina's participation in the Dubai Expo, which was accessed from Jakarta on March 18 (ANTARA/HO-Pertamina)The 2021 transformation helped push up its consolidated net profit (audited) to US$2.046 billion or around Rp29.3 trillion, president director of Pertamina, Nicke Widyawati, said in a statement issued in Jakarta on Tuesday.The figure was almost double compared to the 2020 net profit of Rp15.3 trillion and exceeded the 2021 Corporate Work Plan and Budget (RKAP) target by 154 percent.In 2021, Pertamina transformed its business by increasing efficiency and production, carrying out energy transition, developing oil and gas infrastructure, and implementing the Refinery Development Master Plan (RDMP) project.Widyawati said Pertamina's successful transformation in 2021 was owing to the formation of the oil and gas holding with six sub-holdings: upstream sub-holding, refining and petrochemical sub-holding, commercial and trading sub-holding, gas sub-holding, integrated marine logistics sub-holding, and new and renewable energy sub-holding."This transformation is a strategic step to adapt to future business changes, moving more agile and faster, focusing on broader and aggressive business development," Widyawati said.Pertamina's positive financial performance was also demonstrated by earnings before interest, taxes, depreciation, and amortization (EBITDA) of US$9.2 billion.This shows that Pertamina's finances are in a healthy (AA) and safe condition amid the disruption and geopolitical challenges affecting the global oil, gas, and energy industry, Widyawati said.Pertamina's net profit was the consolidated profit of all subsidiaries from upstream, processing, to downstream.Most of the profit was contributed by the upstream sector's revenue, which surged due to rising Indonesian crude prices (ICP). The downstream sector remained under pressure from the high cost of fuel production, the largest component of which is crude oil, Widyawati said.In 2021, upstream oil and gas production increased from 863 thousand oil barrels equivalent per day (MBOEPD) in 2020 to 897 MBOEPD. Thus, Pertamina contributed more than 60 percent to national oil and gas production.In addition, with Pertamina's massive drilling, production at Rokan Block also increased. Various efficiency programs also resulted in cost savings of US$1.4 billion.Fuel production was also achieved according to the target, so there were no additional imports. Since April 2019, Pertamina is no longer importing solar and Avtur fuel, Widyawati said.Pertamina has also completed the construction of two giant oil and gas tankers, namely VLCC Pertamina Pride and Pertamina Prime, which will be used for the global market.Meanwhile, to improve fuel supply reliability in Eastern Indonesia, Pertamina has built and operated 13 new fuel terminals.Pertamina is also running National Strategic Projects (PSN), including the Balikpapan RDMP Refinery (47 percent completion), Balongan RDMP refinery (68.5 percent completion), Cilacap Green Refinery, Tuban GRR Refinery, as well as other priority projects to strengthen Pertamina's petrochemicals business such as Polypropylene Balongan, Revamping Aromatic TPPI, and Olefin TPPI, she said.Integrated digitization from upstream to downstream has been one of the keys to Pertamina's successful controlling of the production and distribution of fuel, as well as the improvement in the service quality to the community.Through its Integrated Command Center, all operational activities can be monitored online and in real-time. The use of MyPERTAMINA application for cashless payments is increasing, and currently, it has reached more than 22 million users, Widyawati informed.With the 2021 new energy development, in addition to the Biosolar B30 production, the Cilacap Refinery has succeeded in producing renewable diesel (100 percent biodiesel), with a capacity of 3 thousand barrels per day. Contact: Fajriyah Usman, VP Corporate Communications, PT Pertamina (Persero)M: +62 858 8330 8686, Email: fajriyah.usman@pertamina.com, URL: https://www.pertamina.comWritten by: Azis Kurmala, Editor: Suharto (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Jubilee Industries Holdings welcomes strategic investor, value-unlocking and synergies to support further growth ACN Newswire

Jubilee Industries Holdings welcomes strategic investor, value-unlocking and synergies to support further growth

SINGAPORE, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - Catalist-listed Jubilee Industries Holdings Ltd has entered into a Sales and Purchase Agreement (SPA) with UPC Electronics Pte. Ltd. (Purchaser) for the sale of the Company's 14% stake in WE Components Pte. Ltd. (WEC), the Group's EBU (Disposal).The Disposal offers significant synergies with the Purchaser's existing operations and strategic priorities, leveraging WEC's extensive product portfolio and strong presence across Asia. The Hong Kong incorporated Purchaser's main business is the promotion and distribution of products and solutions of semiconductor manufacturers in the People's Republic of China and overseas.The total cash consideration of US$2.1 million received for the Disposal will be utilised for general working capital purposes and the expansion of Jubilee's business.Jubilee's Executive Chairman and Chief Executive Officer, Dato' Terence Tea, said, "The Disposal reflects the deep value of Jubilee's EBU that we have built over the years. Working together with UPC, we are confident in the EBU's long-term growth prospects as we strive to build sustainable value for shareholders."Under Dato' Terence Tea's leadership, Jubilee's EBU has staged a full recovery from the initial impact of Covid-19, recording a 67.4% increase in revenue from S$119.9 million for the 12 months ended 31 March 2021 (FY2021) to S$200.7 million for the same period this year (FY2022).About Jubilee Industries Holdings LtdEstablished in 1993 and listed on SGX-Catalist since 10 July 2009, Jubilee Industries Holdings Limited is a one-stop service provider with two main business segments:1. Mechanical Business Unit (MBU), which is engaged primarily in precision plastic injection moulding (PPIM) and mould design and fabrication (MDF) services (Mechanical Segment); and 2. Electronics Business Unit (EBU), which distributes integrated electronic components. Headquartered in Singapore, Jubilee's production facilities span across Malaysia and Indonesia. Jubilee's products are sold to customers in the United States, the People's Republic of China, Singapore, India, Indonesia, Malaysia, Vietnam and various European countries. For more information, please visit http://www.jihldgs.comIssued on behalf of Jubilee Industries Holdings Limitedby Waterbrooks.com.sgFor media enquiries, please contact:Wayne Koo / Elliot Siow+65 9338 8166 / +65 6381 6347Email: wayne.koo@waterbrooks.com.sg / elliot@waterbrooks.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
「2022年度杰出董事奖」现已接受提名 ACN Newswire

「2022年度杰出董事奖」现已接受提名

HONG KONG, Jun 22, 2022 - (亚太商讯 via SEAPRWire.com) - 香港董事学会宣布「2022年度杰出董事奖」选举正式接受提名。大会将本年度的奖项主题定为「适应转变,持续发展」,旨在表扬在瞬息万变的营商环境下坚定领航,以优秀企管思维及实务策略带领企业适应转变及迈向持续发展的杰出董事及董事会。香港董事学会理事会主席陶荣博士表示:「在面对危机的时候,领袖的领导能力展现在是否能够重新开始思考和定义一些根深蒂固的价值或结构,以及从低谷站起的勇气和魄力。在现时浑沌的环境当中,我们必须不断学习、进步、适应以及改变,务必确保『新常态』是『更好的常态』。适逢香港董事学会25周年,我们将奖项主题订为『适应转变,持续发展』,而这亦是学会多年累积所领略到的精髓—适应力是在瞬息万变的世界中生存所需的最重要特质,而持续发展是每家企业追求的长远目标。我希望各位能踊跃提名在这两个范畴表现出色的董事及董事会,以他们的成功事例为商界同侪带来启发。」 2022年度杰出董事奖筹委会主席何丽康先生表示:「在筹委会讨论今年的奖项主题时,都认为世界局势虽然仍是风云莫测且极具挑战性,但相较之前稍为明朗。因此,我们将奖项主题定为较具掌握力的『适应转变,持续发展』。我们希望表扬在疫情期间逆难而上、助企业创出佳绩的杰出领航人,同时亦希望提醒各界人士要放眼于长远策略,勿忘继续朝可持续发展的目标前进。」香港董事学会行政总裁徐尉玲博士表示:「无论是企业或个人,我们都逐渐习惯在变幻莫测的环境下保持波澜不惊。在站稳脚步后,我们是时候重新朝长远目标进发。董事们身为企业的领袖,必须时刻保持对市场的敏锐,时刻为『下一步』作出部署。例如,Web3.0是最近的一个发展大势,或在不久将来会为我们带来翻天覆地的改变。如果企业领袖对它的认识不足,或有可能错失大好良机。香港董事学会提供多元、创新的课程,真正助会员温故知新,助他们时刻准备好带领企业前进。」今届截止提名日期为2022年8月1日。评选团由本港著名商界领袖、专业人士及规管人员组成,「2022年度杰出董事奖」奖项分为以下类别:公司类别 / 董事类别1. 上市公司 / 1. 执行董事2. 非上市公司 / 2. 非执行董事3. 法定/非分配利润组织* / 3. 董事会注: *「法定/非分配利润组织」是指不派发红利予其股东、会员、董事、雇员或任何人士的组织,其宗旨范围包括慈善福利、社会服务、保健医疗、教育、研究、工商联盟、专业推广、自助支持等但并不限于上列。「董事个人类别」的评选专业准则包括:策略性企业业务功能的效益、赋予董事会效益的贡献、变易、危机及传承管理的贡献、领导才能及其它个人特质和才能,包括董事持续专业发展、商业伦理、及其他杰出表现。「集体董事会类别」的评选准则包括:董事会组合、董事的才能和胜任能力、策略性企业业务功能的效益、策略性计划的制定、推行及表现监控、规范及问责管理、变易、危机及传承管理、董事会发展,包括董事持续专业发展、董事会委员会的效益、商业伦理及其他杰出表现。如欲索取奖项提名表格及相关数据,请浏览香港董事学会网址 www.hkiod.com。有关杰出董事奖杰出董事奖于2001年推出,为亚洲首个同类奖项选举,自此成为企业社群一年一度具影响力的盛事。杰出董事奖选举旨在宣扬良好企业管治的重要性,表扬董事及董事会的优秀董事实务及企业管治,以及提高香港各界对优秀企业管治及董事职能专业化方面的关注。所有奖项均由公众提名。良好的企业管治对各类型组织皆具重要性,为鼓励所有董事实践专业董事守则,此奖项按公司类别及职责划分为不同组别,并从各组别中选出表现卓越的得奖者。公司组别包括上市公司、私人公司及法定/非分配利润组织,职责组别则包括执行董事、非执行董事及董事会。有关过往杰出董事奖详情,请浏览 http://www.hkiod.com/chn/dya-awardees.html。有关香港董事学会香港董事学会为香港代表专业董事的首要组织,其宗旨是通过推广及制定优秀企业管治的标准及支持董事专业发展,以促进企业的成功长远发展。凭借由來自上市公司、公营及私人公司及法定/非分配利润组织的董事组成的广大会员基础,香港董事学会将继续发展多重策略以建立良好的企业管治架构。香港董事学会采用粤语及英语经营业务,其培训计划则以粤语、英语及普通话进行。网址: http://www.hkiod.com。 新闻垂询:纵横公共关系顾问集团有限公司陈 练 +852 2114 4396 brenda.chan@sprg.com.hk邱泽勤 +852 2114 4395 chak.yau@sprg.com.hk传真:+852 2114 49482022年度杰出董事奖查询:香港董事学会苏佩君 +852 2889 4988 odessa.so@hkiod.com任绮欣 +852 2889 1414 joanne.yam@hkiod.com传真:+852 2889 9982 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
GAC Honda Begins Construction of New EV Production Plant JCN Newswire

GAC Honda Begins Construction of New EV Production Plant

BEIJING, CHINA, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - Honda Motor (China) Investment Co., Ltd., a wholly-owned Honda subsidiary in China, announced that GAC Honda Automobile Co., Ltd. (GAC Honda), a Honda automobile production and sales joint venture in China, began construction of its new EV plant, taking a forward step in establishing a suitable EV production system and capability in preparation for an increase in the number of EV models in its product lineup.Overhead view of rendering of GAC Honda's new EV plantGAC Honda's dedicated EV production plant will be newly constructed on a lot with the size of 400,000m2 within the Guangzhou Economic and Technological Development District, Guangzhou City, Guangdong Province, China. The plant is targeted to begin operation in 2024 with an annual production capacity of 120,000 units.With an initial investment plan of 3.49 billion R.M.B., the plant will proactively pursue sustainable initiatives including the use of solar power and other renewable energy sources. Moreover, by adopting a number of advanced production technologies, GAC Honda will strive to make it a highly efficient, smart and low-carbon EV plant.In China, Honda is planning to introduce 10 e:N Series EV models by 2027. GAC Honda?s new EV plant will become a symbolic production operation that supports a broad EV lineup that GAC Honda will roll out in the coming years. It also will serve as a core operation of Honda EV production in China, together with the new EV plant which will be built by Dongfeng Honda Automobile Co., Ltd. (Dongfeng Honda) and is planned to begin operation in 2024.In 2024, when both the GAC Honda and Dongfeng Honda new EV plants become operational, Honda will have a total base annual automobile production capacity of 1.73 million units.Honda will continue to accelerate its electrification efforts toward the realization of carbon neutrality by 2050 and offer attractive products that go beyond customer expectations. For more information, visit bit.ly/3Qx7lpn. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
MHIET’s Indian Subsidiary MVDE Achieves Cumulative Production of 200,000 Industrial-Use, Small Diesel Engines JCN Newswire

MHIET’s Indian Subsidiary MVDE Achieves Cumulative Production of 200,000 Industrial-Use, Small Diesel Engines

TOKYO, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries Engine & Turbocharger, Ltd. (MHIET), a part of Mitsubishi Heavy Industries (MHI) Group, announces that its subsidiary in India, Mitsubishi Heavy Industries-VST Diesel Engines Pvt. Ltd. (MVDE)*, has achieved a cumulative production of 200,000 units of industrial-use, small diesel engines. This achievement was made possible by the acknowledgement of the engine's durability in harsh environments and the manufacturing quality originated in Japan, as well as the high demand for engines to be used in industrial applications including agricultural equipment and generators.MVDE is a subsidiary of MHIET, established in 2007 as a joint venture with V.S.T. Tillers Tractors Ltd. (VTTL), a local agricultural machinery manufacturer. MHIET holds a 96.8% stake in the company, and VTTL 3.2%. MVDE's diesel engines are trusted by OEMs of agricultural machines, generators and other equipment around the world and reached a cumulative production total of 100,000 units in 2018. OEMs in India have been focusing not only on the domestic market, but also Europe and other markets, resulting in a steady increase in the sales of MVDE engines.Taking advantage of the momentum from reaching this milestone, MHIET and MVDE strengthen the sales, procurement, manufacturing and aftersales service further to respond to the growing demand in the Indian market and other markets by utilizing its global network.*For more information on MVDE, visit https://www.mhi.com/group/mvde/ Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Nomination Opens for “Directors Of The Year Awards 2022” ACN Newswire

Nomination Opens for “Directors Of The Year Awards 2022”

HONG KONG, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - The "Directors Of The Year Awards 2022" organised by The Hong Kong Institute of Directors ("HKIoD") is open for nomination now. Themed "From Resilience to Sustainability", the Awards this year recognises directors and boards capable of leading their companies in adapting to changes and, with outstanding governance thinking and practical strategies skills, taking their companies towards sustainable development in the ever-changing business environment.Dr Christopher To, Chairman of HKIoD, said, "Leadership in crisis calls for the ability to rethink and redefine some long-standing values or structure, and also the courage and strength to brave the uphill. In the at large uncertain environment now, we must keep learning, evolving, adapting and changing, to make sure the 'new normal' is a 'better normal'. Marking HKIoD's 25th Anniversary, this year's award is themed 'From Resilience to Sustainability', reflective of what we have learnt over the years. Resilience is the most important quality a company needs to survive in the ever-changing world and sustainability is the ultimate goal of every company. I hope all of you can nominate directors and boards standing out in these two aspects, that we may take as examples to inspire all in the business sector to excel."Mr Richard Ho, Chairman of 2022 Directors Awards Organising Committee, said, "When discussing the award theme this year, the Committee thought though the global scene is still unpredictable and challenging, it has become clearer. Thus, we decided to have 'From Resilience to Sustainability' as the theme easier to grasp. We hope to commend those outstanding leaders who braved the challenges from the pandemic and helped their companies achieve good results, and also to remind those in different sectors to set their eyes on long-term strategy and advance towards their sustainable development goal."Dr Carlye Tsui, CEO of HKIoD, said, "All of us, companies or individuals, have gotten used to staying clam in the turbulent environment. With our feet firmly on the ground, it is time that we head again towards our long-term targets. Directors, as leaders of a company, should be sensitive at all times to changes in the market and plan the 'next step' to take. For example, Web3.0 is the latest and a major trend likely to bring revolutionary changes in the near future to all of us. Business leaders who do not have a good understanding of it might just miss the opportunities that come with it. Offering diverse and innovative courses, HKIoD helps members refresh what has been learnt and acquire new knowledge, so that they may be ready any time to take their companies forward."Nomination for the Awards will close on 1 August 2022. On the Judging Panel are business leaders, professionals and regulatory body representatives in Hong Kong. The Directors Of The Year Awards 2022 recognise excellence in the following categories:Company Categories / Director Categories1. Listed Companies / 1. Executive Directors2. Non-Listed Companies / 2. Non-Executive Directors3. Statutory/Non-Profit-Distributing Organisations* / 3. BoardsNotes: *A non-profit-distributing organisation is defined as an organisation which profits are not distributed to its shareholders, members, directors, employees or any other persons, and with objectives including, but not limited to, charitable welfare, social service, health and medical care, education, research, trade and industrial alliance, professional advancement, self-help support, etc.The selection criteria for winners in the Individual Director Categories include: successful pursuit of strategic corporate business/non-profit functions, contribution to board effectiveness in strategic planning and monitoring of performance, implementing compliance, risk control and accountability measures, managing change and succession, and leadership and other attributes and qualities, including keen at continuing professional development, business ethics and other achievements. As for the Collective Board Categories, the judging criteria include: board composition, effectiveness in pursuing strategic corporate/non-profit functions, development and execution of strategic plans and monitoring of performance, implementing compliance, risk control and accountability measures, managing change and succession, development of the board, effectiveness of board committees, business ethics and other achievements.The Awards nomination form and related information are available on The Hong Kong Institute of Directors website www.hkiod.com.About Directors Of The Year AwardsLaunched in 2001, the Directors Of The Year Awards was the first of its kind organised in Asia. It is now an annual project of impact in the community. Its objectives are to recognise directors and board of directors for outstanding director practices and corporate governance, to publicise the significance of good corporate governance and to promote awareness of good corporate governance and director professionalism in Hong Kong. Nominations are open to the public. As good corporate governance is vital to all types of organisations, and professional practices from directors in all board roles are encouraged, the Awards recognise excellence in categories by company types, including listed companies, private companies and statutory/non-profit-distributing organisations, and categories by roles, including Executive Directors, Non-Executive Directors and Boards. For more details on the previous years' Awards, please visit http://www.hkiod.com/dya-awardees.html.About The Hong Kong Institute of DirectorsThe Hong Kong Institute of Directors is Hong Kong's premier body representing directors to foster the long-term success of companies through advocacy and standards-setting in corporate governance and professional development for directors. A non-profit-distributing organisation with membership consisting of directors from listed and non-listed companies, HKIoD is committed to providing directors with educational programmes and information service and establishing an influential voice in representing directors. With international perspectives and a multi-cultural environment, HKIoD conducts business in biliteracy and trilingualism. Website: http://www.hkiod.com.Media Enquiries:Strategic Public Relations GroupBrenda Chan +852 2114 4396 brenda.chan@sprg.com.hkChak Yau +852 2114 4395 chak.yau@sprg.com.hkFax: +852 2114 4948Directors Of The Year Awards 2022 Enquiries:The Hong Kong Institute of DirectorsOdessa So +852 2889 4988 odessa.so@hkiod.com Joanne Yam +852 2889 1414 joanne.yam@hkiod.comFax: +852 2889 9982 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
G20 committed to financing better pandemic response ACN Newswire

G20 committed to financing better pandemic response

JAKARTA, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - The G20 members and several relevant international organizations agreed to work together to create the Financial Intermediary Fund (FIF) to help countries in need to face any pandemic in the future.Indonesian Health Minister Budi Gunadi Sadikin (L) and Indonesian Finance Minister Sri Mulyani (R) at the first G20 Joint Finance and Health Ministerial Meeting held in Yogyakarta, 21 June. (ANTARA/AstridFaidlatulHabibah)During the 1st G20 Joint Finance and Health Ministerial Meeting held in Yogyakarta on Tuesday, Indonesian Finance Minister Sri Mulyani emphasized the urgency for collaborative work between health and finance sectors to better prepared for future pandemics, considering that the COVID-19 would not be the last."The world is definitely watching us - how the G20 is going to respond with delivering concrete action in pandemic preparedness and response. The world is waiting for us," Mulyani remarked.Furthermore, she also asserted the importance of inclusivity in the work of FIF, led together by the World Health Organization (WHO) and the World Bank, which required the involvement of both developed and developing countries."Only then, we can be effective in preparing to tackle the next global pandemic together," Mulyani stated."I would like to acknowledge the central role of the WHO in fighting pandemic and the importance of including the voice of developing countries in our institutional arrangement to create the most effective system for pandemic preparedness and response," she added.The WHO and the World Bank estimated that US$31 billion is required annually for strengthening global health security, according to WHO Director General Tedros Adhanom Ghebreyesus.About two-third of that fund could come from existing resources but that leaves a gap of US$10 billion per year. Hence, he expects that the FIF would help close that gap.WHO and the World Bank have been cooperating to establish the FIF, which would be overseen by a board that takes a decision on funding allocation supported by a technical advisory panel.Both the board and the technical advisory panel would be supported by the joint WHO-WB secretariat based at the Bank's headquarters in Washington, with assisting staff from the WHO.According to the plan, the Bank will provide financial and administrative leadership at the secretariat, operate as a representative for the FIF, hold and transfer relief funds, as well as provide administrative services.Meanwhile, the WHO will provide technical leadership; coordinate input for the technical advisory panel; and prepare relevant technical documentation, recommendations, and reports for the council.Both the World Bank and WHO will act as implementing entities, along with other global health partners with relevant expertise, including the Global Fund, the Global Alliance for Vaccines and Immunization (GAVI), and the Coalition for Epidemic Preparedness Innovations (CEPI)."We look forward to your active participation in building and financing a FIF that is inclusive, equitable, and effective in making our world safer from pandemics," Tedros noted.To date, the G20 has pushed for an emergency fundraising commitment of around US$1.1 billion from five member countries and one international social organization to mobilize the role of FIF.The pledges came from the United States, the European Union, Germany, Indonesia, Singapore, and the Wellcome Trust.Additionally, Indonesian Health Minister Budi Gunadi Sadikin stated the meeting was not only focusing on the FIF as the source of funds to face future pandemics, but the world must also think about the uses of funds."Because money is (only) half the solution for the health crisis. We need to translate this money into access to vaccines, medicines, and diagnostic tools," he said at a press conference after the joint ministerial meeting.In order to create such access, he explained, the engagement with private sectors as the producers of vaccines, therapeutics, and diagnostics was crucial."We need to talk to them, to engage with them. How can they maintain a certain volume commitment? How then we will be able to distribute equally and very quickly if the next pandemic happens?" he noted.The establishment of FIF is still in the ongoing discussion that will be continued at the next G20 meetings, hosted this year by Indonesia.However, as the G20 President, Indonesia will continue to gather as much as possible support from more countries as well as an international organization even philanthropists, in order for them to be able to contribute to the financing side of pandemic preparedness and response.Written by: Yashinta Difa Pramudyani, Editor: Fardah Assegaf (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Hexagon and Fujitsu Announce Strategic Partnership to Solve Societal Challenges for ‘Trusted Society’ JCN Newswire

Hexagon and Fujitsu Announce Strategic Partnership to Solve Societal Challenges for ‘Trusted Society’

HUNTSVILLE, Ala. and Tokyo, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - Hexagon's Safety, Infrastructure & Geospatial division and Fujitsu Limited will partner to accelerate the development and promotion of use cases to solve societal challenges and contribute to the realization of the 'Trusted Society' -- a sustainable, resilient place where people can live together in peace and prosperity. The partnership was announced today at HxGN LIVE Global 2022, Hexagon's digital technology conference.Hexagon and Fujitsu will work together to provide joint use cases leveraging digital twin technologies and solutions from both companies, including IoT sensors, data processing, AI analysis and advanced data visualization in the cloud and high-performance computing infrastructure. The partners will deploy these technologies to develop joint solutions that deliver richer information and deeper insights to customers in government, the public sector, transportation and utilities to help reduce emissions, increase safety, optimize operations and more."Our goal at Fujitsu is to realize our vision for a 'Trusted Society'," comments Yoshinami Takahashi, EVP and vice head of Global Solution Business Group, Fujitsu. "Partnering with Hexagon will allow us to extend our reach and provide even greater value to cities and regions around the world.""Cities are playing a leading role in solving global challenges, from addressing climate change to eliminating traffic fatalities," says Steven Cost, president, Hexagon's Safety, Infrastructure & Geospatial division. "Our partnership with Fujitsu can help cities put data to work to solve these pressing problems and meet sustainability and safety goals."The new global partnership builds from the companies' work to solve urban sustainability challenges in Europe, including efforts to better manage and understand the impacts of shared mobility services in Germany, including a project with the City of Munich.Hexagon is a global leader in digital reality solutions, combining sensor, software and autonomous technologies. We are putting data to work to boost efficiency, productivity, quality and safety across industrial, manufacturing, infrastructure, public sector and mobility applications. Our technologies are shaping production and people-related ecosystems to become increasingly connected and autonomous -- ensuring a scalable, sustainable future.Hexagon's Safety, Infrastructure & Geospatial division improves the resilience and sustainability of the world's critical services and infrastructure. Our solutions turn complex data about people, places and assets into meaningful information and capabilities for better, faster decision-making in public safety, utilities, defense, transportation and government.Hexagon (Nasdaq Stockholm: HEXA B) has approximately 22,000 employees in 50 countries and net sales of approximately 4.3bn EUR. Learn more at hexagon.com and follow us @HexagonAB.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Hexagon Emily Arnold Global Communications Manager Tel: +1 256.730.2582 E-mail:Emily.arnold@hexagon.comFujitsu Limited Public and Investor Relations Division Inquiries (bit.ly/3rrQ4mB) Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
CT Event Asia to host The 2nd Annual Clean Power & New Energy 2022 ACN Newswire

CT Event Asia to host The 2nd Annual Clean Power & New Energy 2022

KUALA LUMPUR, June 21, 2022 - (ACN Newswire via SEAPRWire.com) - This year, CT Event Asia is all set to bring you the 2nd Annual Clean Power & New Energy 2022, themed "Shaping the Future of Energy in Asia". Happening at the Mandarin Oriental Hotel on 20th-21st July 2022, this conference is the most efficient and targeted event for utility scale renewable companies. Bringing these industries together will create more value for participants by enhancing opportunities to network, broadening the scope of education and providing access to an exclusive audience.Incorporating all renewable technologies will be more convenient and cost-effective for multi-tech businesses as well as companies specializing in wind, utility solar, artificial intelligence in the Energy sector, Green hydrogen energy, Bioenergy, Internet of energy and Engineering in renewable who will benefit from an efficient business development forum that attracts decision makers from large-scale developers, corporate buyers and utilities.Attracting 500+ senior representatives from across the leading utility leaders, Government bodies, Renewable Energy companies, Engineering Procurement, Construction and Management, Economists, Financiers, Power Generation and Investors to discover how the Economic, Financial and Political framework for Energy is evolving, and to assess the implications of growing renewable deployment for the future shape of the Energy Industry. Here is our speaker list!Join us now to get more insights from industry leaders on the future of Energy in Asia and meet our Sponsors and Partners as well with all of this to explore, our 2nd Annual Clean Power and New Energy 2022 is set out to be bigger than ever! Here's our list of Sponsors and Partners.The 2nd Annual Clean Power & New Energy 2022 website has full details about the program. Interested parties can visit the website here or request for the event brochure here.To get in touch with our team for enquires relating to this event, feel free to reach out to:CamaraPartnership DirectorCT Event Asia+60 16 283 2660 | +03 2710 7756camara@cteventasia.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

抗疫助稳 兴业银行为外贸企业纾困解难

HONG KONG, Jun 21, 2022 - (亚太商讯 via SEAPRWire.com) - 近日,记者从兴业银行了解到,该行认真落实党中央、国务院关于外贸保稳提质的工作部署,加大跨境融资信贷投放力度,加强跨境人民币业务支持,大力发展外贸新业态金融服务,全力支持外贸企业复工复产和全球展业。今年1-5月,兴业银行跨境人民币收支5123亿元,同比增长158%;跨境融资余额1813亿元,较年初增长24%。“多亏了兴业在线跨境人民币结算绿色通道,原先办理一笔跨境收款的资金解付至少需要半天至一天时间,现在半个小时内搞定,有效缓解了我们经营资金周转难题。”北京一家电子行业头部企业财务负责人感慨道。目前兴业银行北京分行已为该企业办理跨境人民币结算逾100亿元,跨境人民币在线绿色通道,正为国内众多外贸类企业的进出口业务保驾护航。数据显示,1-5月,兴业银行实现本外币跨境结算量1253亿美元,同比增长19%。疫情之下,兴业银行持续完善跨境在线融资体系,近期该行将推出“跨境E贷”在线融资产品,基于数据模型,可实现线上为小微出口企业核定信贷额度和放款,将大幅提升小微企业的融资效率,为出口企业提供便捷、高效、低成本融资服务,助力企业拓展海外市场。外贸新业态新模式是推动我国外贸转型升级和高质量发展的新动能,兴业银行持续推进外贸新业态项下跨境业务发展,服务好跨境电商、海外仓、市场采购贸易、外贸综合服务、新型离岸贸易等领域,打通外贸新业态资金流转链路,为外贸企业保稳提质注入金融活水。以跨境电商为例,兴业银行搭建跨境电商综合服务平台,服务跨境电商进出口企业200多户,前5个月带动跨境结算量7.31亿美元。“兴业银行将加快推进跨境电商综合服务平台升级,加强与跨境电商平台、支付公司等外部平台和机构的合作,构建跨境贸易生态圈,为贸易新业态企业提供全方位金融支持。”兴业银行国际业务部负责人表示。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
MOKWHEEL Unveils Basalt, An Epic Power Backup Ebike with the Most Innovative Features SeaPRwire

MOKWHEEL Unveils Basalt, An Epic Power Backup Ebike with the Most Innovative Features

New York City, NY, June 21, 2022 (SEAPRWire) – This month, Mokwheel has announced its highly anticipated Basalt Ebike line. The new electric bicycle line will be available in a step-over and step-through model, which are compatible with power inverters and batteries for the electric bike to use. The Basalt Ebike, in its entirety, holds power and features integrated power station technology that the market has never seen before. With a series of patented power station concept manufacturers in mind, Mokwheel is ready to take off this revolutionary technology and start making history in the e-mobility industry. The Basalt line plans to work toward greener solutions for clean transportation efficiently. “Our goal is to be the leading force of revolutionizing intelligent transportation products to make the world more sustainable and efficient,” the company revealed. Key features of Mokwheel Basalt Ebike include: 1. Portable power station that can be utilized to charge up devices and appliances on the go. 2. A massive battery capacity allows an extended range of up to 85-miles on a single charge. 3. Flexible and adaptive hydraulic front fork for smoothing bumps and improving off-road capability. 4. The ability to customize different riding styles with pedal-assist and throttle mode. 5. Two 26*4-inch fat tires improve traction and grip with shock absorption capacity. 6. IPX5-rated water resistance allows users to ride in most weather conditions. The Ebike also hosts technology that lets you experience the freedom of the open road without limiting your movement or compromising your safety. Tektro Auriga E-Comp hydraulic brakes, with adjustable suspension and two 26-inch fat tires, provide tremendous grip and mechanical stability to allow you to ride with confidence in a variety of unpredictable terrain. “Not only are we developing innovative electric bikes that are already on the market, but we want to overcome the barrier of making Ebikes smarter and bringing something new to the public that they have never seen before. We want to provide value to our customers and society,” said Denny, CEO of Mokwheel. The Mokwheel Basalt Ebike campaign kicks off in Jun. 26th on Indiegogo, a crowdfunding platform. Follow the Mokwheel Basalt campaign and turn on the notification to receive an early bird discount. Mokwheel is a start-up specializing in creating intelligent, practical, and innovative electric vehicles that change the face of the electric transportation field. Based on the company’s proprietary power station technology, Mokwheel creates ground-breaking electric bicycle products to revolutionize the transportation industry. The company focuses on quality and prioritizes products that can provide meaningful experiences. The Mokwheel team is led by Denny L, a young entrepreneur, dedicated to outshining the existing electric bicycle market by providing user-friendly products that meet the demands of today’s consumers. Media Contact Brand Name: Mokwheel Email: support@mokwheel.com Web: https://www.mokwheel.com/ SOURCE: Mokwheel The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Mazda 787B to Drive Demo Laps in Le Mans Classic 2022 JCN Newswire

Mazda 787B to Drive Demo Laps in Le Mans Classic 2022

HIROSHIMA, Japan, Jun 21, 2022 - (JCN Newswire via SEAPRWire.com) - Mazda Motor Corporation announced that the Mazda 787B, symbol of Mazda's "never stop challenging" spirit, will do demonstration laps(1) at Le Mans Classic 2022 to be held from June 30 to July 3.1991 Le Mans winner, Mazda 787B, at Le Mans drivers' parade on June 10, 2011Equipped with a four-rotor rotary engine, the Mazda 787B became the first Japanese automobile to win the 24 Hours of Le Mans endurance race in 1991. For the first time in almost a decade, spectators will be able to witness the thrilling and distinctive sound of the Mazda 787B's rotary engine at Le Mans Classic 2022. The last two opportunities to see the legendary vehicle being at the 90th anniversary of the 24 hours of Le Mans in 2013 and the 20th anniversary of Mazda's victory at Le Mans in 2011.The Mazda 787B was due to run at Le Mans Classic last year to mark the 30th anniversary of its victory, unfortunately the event itself was postponed to this year due to Covid-19.Thanks to support from model car company, Spark, 29-time competitor in the 24 Hours of Le Mans, Yojiro Terada dubbed as "Mr. Le Mans" in Japan, will drive the Mazda 787B during demonstration laps on July 1 and 2 when Group C racing will be held.Le Mans Classic is a very popular event in which numerous famed racing cars that have previously competed in the 24 Hours of Le Mans(2) gather and make an appearance every two years on the Circuit de la Sarthe. In Group C, entry vehicles are divided by historical period and compete in 60-minute races. This year's entries will include cars that have cemented their names in history such as the Toyota Tom's 85C, the Porche 962, the Jaguar XJR and the Peugeot 905.For Mazda 787B, visit the special website commemorating the 30th anniversary of Mazda's victory at Le Mans, www.mazda.com/en/innovation/lemans30th/. (1) In case of rain or other poor weather conditions, the demonstration laps by Mazda 787B may be cancelled.(2) 2022 24 Hours of Le Mans marked 99 years since the event first ran in 1923. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. ACN Newswire

The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

HONG KONG, Jun 21, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, today announced that, on 10 June 2022, the mechanism of action of its flagship product SM03 (Suciraslimab) is successfully published in the Journal of Immunology, a reputable journal on immunology in the US (link to the paper: https://www.jimmunol.org/content/early/2022/06/10/jimmunol.2100820 ).Figure: Mechanism of Action of SM03 (Suciraslimab)The Journal of Immunology (the JI), founded in 1916 and managed and published by the American Association of Immunologists, is the world's leading peer-reviewed journal in the field of immunology, with a 5-year impact factor of 6.029 (Journal Citation Reports 2020), and publishes the latest immune-related findings in basic and clinical research in the field of immunology. It also publishes the latest research papers in the field of immunology, including cellular immunology, immunochemistry and molecular immunology, immunogenetics and immunomodulation, immunopathology and clinical immunology, immunopharmacology, microbial immunology, oncology and transplantation.The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA). The patient enrollment for the Phase III clinical trial in China has been completed by the end of 2021, with a total of 530 subjects recruited. The trial is a multi-centre clinical study led by Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, with clinical centres in 44 hospitals including Gulou Hospital of Nanjing University School of Medicine, the Second Hospital of Harbin Medical University and the First Hospital of Shanxi Medical University. The Company expects to lock the database at the end of June this year, read out the results of the Phase III clinical trial data in early August and will have biologics license application (BLA) in 2023. In addition, the development of Suciraslimab has also received support from the 863 Program, the "12th Five-Year Plan" and the "13th Five-Year Plan" for development of major new drugs, as well as the green channel for "prioritized review and approval" by the Center for Drug Evaluation (CDE). Previously, a phase II clinical trial led by Peking Union Medical College Hospital has demonstrated the efficacy and safety of Suciraslimab for the treatment of RA.The Company's flagship product Suciraslimab is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis. The core competitive advantage of this product over the standard therapies currently on the market is its novel and unique mechanism of action, which ensures that Suciraslimab is comparable to other products in terms of efficacy, while having significant advantage in terms of safety, which is a major concern for patients on long-term medication for autoimmune diseases.Under normal operation of human's immune system, B-cell receptor (BCR) pathway would be activated and create strong signals in response to foreign ("non-self") antigens and trigger a series of B-cell immune responses. To differentiate from our "self" antigens, our body would recruit molecules, like SHP-1, to inhibit or reduce BCR-induced signaling, thereby suppressing B-cell immune responses. We suggested that the recruitment of these molecules such as SHP-1 could be achieved by conversion of cis-binding CD22 to trans-binding CD22, thus suppressing relevant immune responses. Due to ageing or genetic predisposition, patients with autoimmune diseases such as RA are unable to convert cis-binding CD22 to trans-binding CD22, and are thus unable to recruit immunosuppressive molecules such as SHP-1 to inhibit or reduce the transmission of antigenic stimuli from B-cell receptors to B-cells, which then generate a series of immune responses, such as the secretion of large amounts of antibodies to attack autoantigens. Our flagship product, Suciraslimab, can facilitate the conversion of cis-binding CD22 to trans-binding CD22, forming a stable CD22 trans-binding structure, thereby restoring the tolerance of B-cells to autoantigens and inhibiting a series of relevant immune responses by B cells to attack the body.Historical data shows that Suciraslimab has a significant safety advantage compared to other products with comparable efficacy currently available in the market. Existing RA therapies include traditional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as methotrexate (MTX), biologic DMARDs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-6 receptors and other targets, as well as targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors and other small molecule drugs, all of which have played an important role in the remission of RA patients. However, most of the mechanisms of action of existing RA therapies will result in the depletion or death of B cells, which can have a series of side effects on human's autoimmune system, thus posing a long-term risk for patients with autoimmune diseases who require long-term medication, as the weakening of the immune system will naturally lead to the development of other debilitating diseases. In contrast, the mechanism of action of Suciraslimab is very different from that of existing therapies on the market. We only inhibit the B-cell related immune response by altering the binding of CD22 and recruiting related inhibitory molecules. Suciraslimab only inhibits the autoimmune response by regulating the function of B-cells and does not damage the B-cells and does not affect the normal function of B-cells in the immune system. Therefore, Suciraslimab has a significant safety advantage over other products currently available on the market.The autoimmune disease drug market has been touted as the next gold mine after oncology drugs. As the "king of drugs" in the world, Humira has topped the global drug ranking for eight years with sales of US$19.832 billion in 2020, making other drugs "bow down". Globally, pharmaceutical giants are focusing on the research and development of drugs in the rheumatic immune field, with the most prominent ones including Pfizer, Novartis, Johnson & Johnson and AbbVie, all with more than a dozen products in development or marketed in their respective pipelines. The global autoimmune disease drugs market is valued at US$113.7 billion in 2018 and is expected to reach US$152.3 billion by 2023 at a CAGR of 6.0%. The market for autoimmune disease drugs in China is expected to grow from RMB13.4 billion in 2018 to RMB37.7 billion in 2030 at a CAGR of 23%. Driven by the global trend of innovation, R&D in rheumatic immune field in China is also gaining momentum. As a leading pharmaceutical innovator in China, Hengrui Pharma has also adopted a strategy of early development, target optimization and expansion of indications in the rheumatic immune field, aiming to fully capitalize on the rapid development of the autoimmune disease market in China. This indicates that SinoMab's mission and vision to become a global leader in innovative therapies for immune and other debilitating diseases are in line with the development trend of the entire pharmaceutical industry. In the foreseeable future, it is believed that SinoMab will help more and more patients suffering from autoimmune diseases and become a leading global biopharmaceutical company focusing on innovative therapies for autoimmune diseases.In addition to its flagship product Suciraslimab, the Company's core product SN1011 has an expanding scope of indications and continues to receive regulatory approval for new drug applications in China and abroad, and also expects to rapidly initiate Phase II clinical trials for pemphigus vulgaris (PV), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and neuromyelitis optica spectrum disorder (NMOSD) this year. SinoMab also dosed first healthy subject in Phase I clinical trial of its major product SM17 in the U.S. in June 2022. By targeting upstream mediators of the Th2 inflammatory cascade, SM17 is able to control inflammatory airway diseases such as asthma caused by the immune cascade at a relatively early stage and is expected to benefit a large number of patients with severe uncontrolled asthma by satisfying unmet medical needs.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for RA in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
中国抗体的旗舰产品舒西利单抗SM03的作用机理在美国免疫领域权威期刊the Journal of Immunology上成功发表 ACN Newswire

中国抗体的旗舰产品舒西利单抗SM03的作用机理在美国免疫领域权威期刊the Journal of Immunology上成功发表

HONG KONG, Jun 21, 2022 - (亚太商讯 via SEAPRWire.com) - 中国抗体制药有限公司(“中国抗体”或“公司”,连同其附属公司,统称“集团”;股份代号:3681.HK),一家专注于研究、开发、制造及商业化免疫疾病创新疗法的香港生物制药上市公司,主要研制以单克隆抗体为基础的生物药,欣然宣布,其旗舰产品SM03舒西利单抗(Suciralimab)的作用机理已于2022年6月10日在美国免疫领域权威期刊the Journal of Immunology上成功发表(论文链接:https://www.jimmunol.org/content/early/2022/06/10/jimmunol.2100820 )。图:舒西利单抗SM03(Suciraslimab)作用机理The Journal of Immunology(the JI),于1916年创刊,由美国免疫学家协会管理和出版,是世界上免疫学领域的顶级同行评鉴刊物,5年影响因子为6.029(2020年期刊引文报告),发布免疫学领域在基础研究和临床研究上的和免疫相关的最新发现,同时发表免疫学领域的最新研究论文,包括细胞免疫学、免疫化学和分子免疫学、免疫遗传学和免疫调节、免疫病理学和临床免疫学、免疫药理学、微生物免疫学、肿瘤和移植。公司旗舰产品舒西利单抗SM03(Suciraslimab)为全球首项用以治疗类风湿性关节炎的潜在抗CD22单抗。该产品已于2021年底在中国完成III期临床试验受试者入组,合计招募530例受试者。该试验为由中国医学科学院北京协和医院牵头的多中心临床研究,临床中心包括南京大学医学院附属鼓楼医院、哈尔滨医科大学附属第二医院、山西医科大学第一医院等44家医院。公司预计今年6月底进行锁库,8月初读出III期临床试验数据结果,并将于2023年申请新药上市(BLA)。此外,舒西利单抗(Suciraslimab)的研发也获得了863计划、“十二五”及“十三五”重大新药创制专项支持,且享受国家药品评审中心(CDE)“优先审评审批”绿色通道。此前,由北京协和医院领导的II期临床试验已验证舒西利单抗(Suciraslimab)对类风湿关节炎治疗有较好的疗效性及较高的安全性。公司旗舰产品舒西利单抗(Suciraslimab)是全球首项用于治疗类风湿性关节炎的潜在抗CD22单抗。该产品与目前市场上现有标准疗法的核心竞争优势在于其新颖独特的作用机理,保证了舒西利单抗在与其他产品疗效相当的情况下,在安全性方面有显着的优势,而安全性正是长期用药的自身免疫疾病患者需要关注的核心问题。在人体免疫系统正常运行的前提下,当外来抗原入侵时,B细胞受体通路会被激活,向B细胞传递抗原刺激信号,引发一系列B细胞免疫反应。而在面对自身抗原时,正常的机体会招募免疫抑制分子如SHP-1,通过阻止或是减弱B细胞受体通路向B细胞传递抗原刺激信号来抑制B细胞相关免疫反应。我们认为,通过转变CD22的结合方式,即CD22从顺式结合转变为反式结合可以达到招募这类免疫抑制分子,如SHP-1,进而达到抑制相关免疫反应的作用。由于年龄或是遗传倾向等原因,RA等自身免疫疾病患者在面对自身抗原时,RA患者的CD22不能从顺式结合方式转变为反式结合,进而不能够招募例如SHP-1的免疫抑制分子来抑制或是减弱B细胞受体向B细胞内传递抗原刺激信号,B细胞接受到抗原刺激信号后,就会产生一系列免疫反应,如分泌大量抗体来攻击自身抗原。而我们的旗舰产品舒西利单抗(Suciraslimab)可以帮助CD22由顺式结合方式转变为反式结合,形成稳定的CD22反式结合结构,进而恢复B细胞对自身抗原的容忍度,抑制B细胞发生一系列相关免疫反应攻击自身机体。通过历史数据与目前市场现有其他产品相比,舒西利单抗(Suciraslimab)在疗效相当的情况下,在安全性方面,相对其他产品有显着的优势。现有RA疗法从甲氨蝶呤(MTX)等传统合成改善病情抗风湿药(csDMARDs),到靶向肿瘤坏死因子(TNF)、白介素(IL)-6受体等靶点的生物制剂DMARDs(bDMARDs),以及靶向合成DMARDs(tsDMARDs),例如Janus激酶(JAK)抑制剂等小分子药物,这些新型药物的引入,对RA患者的病情缓解都起到了重要的作用。但是目前现有RA疗法的大部分作用机理都会导致B细胞的耗竭或是衰亡,对人体自身免疫系统都会产生一系列的副作用,这对需要长期用药的自免疾病患者来说存有长期隐患,免疫系统的衰弱自然而然的会引发其他衰竭性疾病的发生。但是舒西利单抗的作用机理却与目前市场的现有疗法截然不同,我们只是通过改变CD22的结合方式,招募相关抑制分子,进而抑制B细胞相关免疫反应,舒西利单抗只是通过调节B细胞的功能来抑制自身免疫反应,并未损伤到B细胞,不影响B细胞在免疫系统中发挥正常作用。因此,舒西利单抗在相对于目前市场上已有的其他产品,在安全性方面有显着的优势。自身免疫疾病用药市场被誉为继肿瘤之后的下一个金矿。修美乐作为全球“药王”,雄踞全球药物榜首长达8年,2020年198.32亿美元的销售额令其他药品“俯首称臣”。放眼全球,制药巨头十分关注风湿免疫领域药物的研发,最突出的包括辉瑞、诺华、强生和艾伯维,管线中均有十余个在研或上市的产品。全球自身免疫疾病药物市场2018年的市场规模为1,137亿美元,且预计到2023年将达到1,523亿美元,复合年增长率为6.0%,中国自身免疫疾病药物的市场规模预计将从2018年的134亿元人民币增长到2030年的377亿元人民币,复合年增长率为23%。受全球创新浪潮的冲击,我国风湿免疫领域的研发热情同样高涨,恒瑞医药作为国内创新药龙头,在风湿免疫领域也采取了早布局、优靶点和广适应症等策略,希望能够充分享受国内自身免疫疾病市场快速发展的红利。可见中国抗体致力成为免疫性疾病及其他衰竭性疾病创新疗法的全球领导者的使命与愿景是迎合整个医药行业的发展趋势的,在可以预见的未来,相信中国抗体可以造福越来越多受自身免疫疾病困扰的患者,成为全球领先的以自身免疫疾病创新疗法为主的生物制药公司。除旗舰产品舒西利单抗外,公司核心产品SN1011的适应症范围不断扩大,新药研究申请不断获得海内外监管机构的批准,也预计在今年快速启动天疱疮(PV)、多发性硬化症(MS)、系统性红斑狼疮(SLE)、视神经脊髓炎(NMOSD)的二期临床试验,主要产品SM17也在今年6月份在美国刚刚完成临床I期试验首例健康受试者给药,通过靶向Th2细胞相关炎性上游细胞因子通路的疗法,能够在较前端控制免疫级联反应引发的哮喘等炎性气道疾病,希望能够为广大未被满足治疗需求的严重不受控制的哮喘疾病患者带来福音。关于中国抗体制药有限公司中国抗体制药有限公司专注于研究、开发、制造及商业化免疫性疾病疗法。公司注重创新研发,其旗舰产品SM03为全球首项用以治疗类风湿关节炎的潜在抗CD22单抗,已在中国进入类风湿关节炎三期临床试验,并被列为国家十三五重大新药创制专项重大项目。此外还有多个同类靶点首创(First-in-target)及同类首创(First-in-class)在研药物,部分已处于临床阶段,适应症范围覆盖类风湿性关节炎、系统性红斑狼疮、寻常型天疱疮、非霍奇金氏淋巴瘤、哮喘等具有重大未满足临床需求的疾病。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More